The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer.
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); ImmuneOncia (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Synermore Biologics (Inst); Taiho Pharmaceutical (Inst); Top Alliance BioScience (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); Vertex (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bayer; Daiichi Sankyo; Vedanta Biosciences
 
Michael Iglesia
No Relationships to Disclose
 
Katrina Sophia Pedersen
Consulting or Advisory Role - Array BioPharma; Bayer; Novartis; Pfizer
Speakers' Bureau - Clinical Care Options; WebMD
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Ipsen (Inst); Merck (Inst); Natera (Inst); Nouscom (Inst); Novartis (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Array BioPharma; BeiGene; Nouscom
Other Relationship - UpToDate
(OPTIONAL) Uncompensated Relationships - NCCN
 
Patrick Grierson
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Pancreatic Cancer
 
Zishuo Ian Hu
No Relationships to Disclose
 
Rama Suresh
No Relationships to Disclose
 
Benjamin R. Tan
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Merck Serono (Inst); Roche/Genentech (Inst); TYME (Inst)
 
Nikolaos Trikalinos
Research Funding - Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst)
 
Olivia Aranha
Research Funding - Ipsen (Inst); Merck (Inst); Pfizer (Inst)
 
Katherine Navo
No Relationships to Disclose
 
David G. DeNardo
No Relationships to Disclose
 
Matthew A. Ciorba
No Relationships to Disclose
 
Katlyn Kraft
No Relationships to Disclose
 
Feng Gao
No Relationships to Disclose
 
Elizabeth Martinez
No Relationships to Disclose
 
Reinhard von Roemeling
Employment - Curis
Leadership - Curis
 
Felix Geissler
Employment - Curis
Leadership - Curis
 
Kian-Huat Lim
Honoraria - Jacobio
Research Funding - Aclaris Therapeutics